Clinical Trials
Dive into the world of clinical trials, where medical innovations are put to the test. Discover ongoing trials, their methodologies, and results. Stay informed about the latest breakthroughs and promising treatments in development. Understand the rigorous process of bringing new therapies to market.
Vertex Halts Phase 2 Lung Therapy, Reevaluates DMD Drug’s Clinical Path
Vertex Pharmaceuticals anticipates a “milestone-rich period” ahead, but there are updates regarding two of its candidates. The biotech has decided ...
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Ventyx Biosciences discovered that even a seemingly successful clinical trial may not be enough to support a drug’s advancement, as ...
Imbria Pharmaceuticals Clears Safety Hurdles in Phase 2 Heart Failure Trial, Paving the Way for Promising Late-Stage Development
Imbria Pharmaceuticals has achieved positive results in a phase 2 trial for its heart failure medication. The Boston-based biotech, in ...
Akeso’s Cadonilimab Achieves Significant Overall Survival in Severe Gastric Cancer Patients
Akeso’s bispecific antibody has demonstrated a significant improvement in overall survival for first-line patients with severe gastric cancer or gastroesophageal ...
Astellas’ Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment
Astellas made a significant acquisition of Iveric Bio earlier this year, primarily motivated by the potential of Iveric’s geographic atrophy ...
MoonLake’s IL-17 Drug Gains Momentum with New Phase 2 Success
MoonLake Immunotherapeutics has achieved promising results in a phase 2 trial for its IL-17 inhibitor, sonelokimab, aimed at treating inflammatory ...
Kodiak’s Eye Drug Revival Spurs Renewed FDA Approval Bid
Kodiak Sciences had previously abandoned its tarcocimab tedromer program following disappointing results in two phase 3 trials. However, a recent ...
Travere Fights for FDA Approval Despite Filspari’s Trial Endpoint Miss
Travere Therapeutics has recently encountered setbacks in two critical trials involving their drug Filspari, with implications for its accelerated approval ...
Tonix Pharmaceuticals Abandons Depression Drug Post-Phase 2 Failure
Tonix Pharmaceuticals has experienced a setback in its pipeline as it discontinues the development of a major depression disorder (MDD) ...
C4 Therapeutics Halts Cancer Project Post Phase 1/2 Trial Setback
C4 Therapeutics has made a strategic decision to discontinue the development of CFT8634, an oral BRD9 degrader, following a phase ...
Catalent Braces for Potential Revenue Setback Following Sarepta’s Gene Therapy Trial Disappointment
Catalent, having overcome the challenges posed by the pandemic, now faces another potential setback in the form of what analysts ...
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Eisai, Biogen’s Leqembi reduces amyloid in Alzheimer’s, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Alnylam, Biogen show gene-silencing data for Alzheimer’s therapies
This week, Alnylam and Biogen took a significant step toward redefining the landscape of Alzheimer’s disease treatment by revealing promising ...
Pfizer, BioNTech ready flu-COVID combo vaccine for phase 3 trial
In an exciting race reminiscent of their previous encounters, Pfizer and BioNTech have once again taken on their recurring competitor, ...
BioSenic seeks to survive cash crunch and enter phase 3 for GvHD drug
BioSenic, the Belgian biotech born from the merger of Bone Therapeutics and Medsenic last year, is devising a survival plan ...
GSK’s RSV vaccine poised for label expansion after trial success
Five months after GSK made history by securing FDA approval for its respiratory syncytial virus (RSV) vaccine, Arexvy, the company ...
Araclon’s Alzheimer’s vaccine shows promise in phase 2 trial
Araclon Biotech, a subsidiary of Grifols, has unveiled promising early evidence regarding the effectiveness of its Alzheimer’s disease vaccine. In ...
Tremfya clears psoriasis in people of color, first study of its kind shows
The journey to improved treatments for psoriasis, a challenging skin condition, has been long and complex. Despite advances, some patient ...
J&J’s dengue pill shows antiviral activity in human trial, could prevent millions of infections
Amidst Johnson & Johnson’s strategic restructuring in the infectious disease and vaccine divisions, one resilient contender has emerged. JNJ-1802, an ...
BMS and Halozyme announce positive results for subcutaneous Opdivo in cancer patients
Following the discontinuation of an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb (BMS) has achieved success with a more ...
Takeda’s Alofisel fails to meet primary endpoint in phase 3 trial for Crohn’s disease complication
Takeda, following its decision to remove an early-stage Crohn’s disease candidate from its pipeline earlier this year, is now contending ...
Evelo seeks new partner after microbiome platform fails to beat placebo
In a series of unfortunate turns, Evelo Biosciences, a biotech company backed by Flagship Ventures and that went public in ...
AbbVie’s Skyrizi beats J&J’s Stelara in head-to-head Crohn’s disease trial
AbbVie’s Skyrizi has notched a resounding victory over Johnson & Johnson’s biologic drug Stelara in treating Crohn’s disease, as revealed ...
Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets
In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...
Sotio halts trials of IL-15 drug in solid tumors due to lack of efficacy, casting doubt on cytokine’s potential
Sotio Biotech has decided to halt ongoing studies of its IL-15 superagonist, nanrilkefusp alfa, due to insufficient efficacy in clinical ...
Roche’s BTK inhibitor shows potential to cross blood-brain barrier in MS trial
Roche is touting its multiple sclerosis (MS) drug as a potential game-changer in the field, asserting that it has achieved ...
Novo’s Ozempic shows promise in kidney disease, but DaVita questions its real-world benefits
Novo Nordisk’s GLP-1 blockbuster Ozempic appears to be making significant strides in the treatment of chronic kidney disease (CKD), potentially ...
Leo Pharma reveals positive results for its JAK cream in hand eczema, competing with Incyte’s Opzelura
In February, Leo Pharma created a buzz by announcing the success of its JAK-inhibitor cream, delgocitinib, in a phase 3 ...
Lilly’s mirikizumab shows promise in Crohn’s disease after failing in psoriasis
After a previous setback when the FDA withheld approval for mirikizumab in ulcerative colitis due to manufacturing issues, Eli Lilly’s ...
